Need professional-grade analysis? Visit stockanalysis.com
$7.36B
82.52
N/A
N/A
Krystal Biotech Inc (KRYS) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $247.09, down 1.82% from the previous close.
Over the past year, KRYS has traded between a low of $123.36 and a high of $291.93. The stock has gained 32.1% over this period. It is currently 15.4% below its 52-week high.
Krystal Biotech Inc has a market capitalization of $7.36B, with a price-to-earnings ratio of 82.52.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.